Published in PLoS One on January 11, 2013
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science (2017) 1.21
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer (2014) 1.14
Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer (2014) 1.07
Prostate Cancer Stem Cells: Research Advances. Int J Mol Sci (2015) 0.84
SOX2 expression in the developing, adult, as well as, diseased prostate. Prostate Cancer Prostatic Dis (2014) 0.83
SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. Lung Cancer (2014) 0.83
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate (2014) 0.83
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr Relat Cancer (2015) 0.81
DNA methylome changes by estradiol benzoate and bisphenol A links early-life environmental exposures to prostate cancer risk. Epigenetics (2016) 0.79
Androgen receptor genomic regulation. Transl Androl Urol (2013) 0.79
Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. Oncotarget (2015) 0.79
Prostate Cancer Stem-like Cells Contribute to the Development of Castration-Resistant Prostate Cancer. Cancers (Basel) (2015) 0.79
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget (2016) 0.79
MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity. Oncotarget (2016) 0.78
SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. Oncotarget (2016) 0.78
Ecotropic viral integration site 1, a novel oncogene in prostate cancer. Oncogene (2016) 0.78
NANOG reprograms prostate cancer cells to castration resistance via dynamically repressing and engaging the AR/FOXA1 signaling axis. Cell Discov (2016) 0.77
Stem cells in genetically-engineered mouse models of prostate cancer. Endocr Relat Cancer (2015) 0.77
Sox2 gene amplification significantly impacts overall survival in serous epithelial ovarian cancer. Reprod Sci (2014) 0.77
Deregulation of MiR-34b/Sox2 Predicts Prostate Cancer Progression. PLoS One (2015) 0.77
The Androgen Receptor Bridges Stem Cell-Associated Signaling Nodes in Prostate Stem Cells. Stem Cells Int (2016) 0.76
Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer. Br J Cancer (2013) 0.76
A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer. Elife (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell (2006) 120.51
Core transcriptional regulatory circuitry in human embryonic stem cells. Cell (2005) 34.93
Integration of external signaling pathways with the core transcriptional network in embryonic stem cells. Cell (2008) 28.29
Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res (2005) 13.89
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res (2008) 6.38
Identification of a cell of origin for human prostate cancer. Science (2010) 6.33
A high-efficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell (2008) 5.99
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med (1999) 4.20
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Pluripotency factors in embryonic stem cells regulate differentiation into germ layers. Cell (2011) 3.53
Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res (2008) 3.32
The transcriptional foundation of pluripotency. Development (2009) 3.21
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem (2008) 3.01
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res (2002) 2.99
Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer (2005) 2.84
Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia (2005) 2.62
Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells (2009) 2.59
Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell Stem Cell (2012) 2.49
Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A (2011) 2.46
Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer (1998) 2.36
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene (2011) 2.22
Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res (2007) 2.22
SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One (2010) 2.21
Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol (2007) 2.09
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer. Oncogene (2011) 1.78
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One (2010) 1.69
Integrated expression profiling and ChIP-seq analyses of the growth inhibition response program of the androgen receptor. PLoS One (2009) 1.68
SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol (2011) 1.66
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate (2003) 1.60
In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem (2004) 1.57
Prediction and testing of novel transcriptional networks regulating embryonic stem cell self-renewal and commitment. Cell Stem Cell (2007) 1.56
Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res (2001) 1.54
SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol (2011) 1.48
Androgen receptor outwits prostate cancer drugs. Nat Med (2004) 1.44
Epigenetic control of embryonic stem cell fate. J Exp Med (2010) 1.40
Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res (2012) 1.40
SOX2 amplification is a common event in squamous cell carcinomas of different organ sites. Hum Pathol (2011) 1.40
Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ (2002) 1.33
In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate (2009) 1.33
Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Mol Cell Biochem (2010) 1.32
Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer (2008) 1.31
Molecular basis of pluripotency. Hum Mol Genet (2008) 1.31
Sox2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med (2010) 1.25
Androgen induces differentiation of a human papillomavirus 16 E6/E7 immortalized prostate epithelial cell line. J Endocrinol (2001) 1.22
A novel approach for the construction of multiple shRNA expression vectors. J Gene Med (2007) 1.21
Prostate stem cells and benign prostatic hyperplasia. Prostate (2008) 1.12
Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One (2010) 1.09
Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clin Biochem (2011) 1.06
Combinatorial androgen receptor targeted therapy for prostate cancer. Endocr Relat Cancer (2006) 1.05
Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate (2010) 1.01
Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res (2012) 0.98
Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate (2011) 0.96
OCT4 expression in human non-small cell lung cancer: implications for therapeutic intervention. Interact Cardiovasc Thorac Surg (2009) 0.92
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate (2003) 0.90
Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res (2006) 4.50
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Six2 is required for suppression of nephrogenesis and progenitor renewal in the developing kidney. EMBO J (2006) 3.26
Aire-dependent thymic development of tumor-associated regulatory T cells. Science (2013) 3.23
Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell (2011) 3.07
Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res (2008) 2.18
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res (2006) 2.02
Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature (2007) 2.01
Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol (2009) 1.78
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Tubulocystic carcinoma of the kidney: clinicopathologic analysis of 31 cases of a distinctive rare subtype of renal cell carcinoma. Am J Surg Pathol (2009) 1.63
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.61
Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol (2008) 1.60
The impact of running versus interrupted anastomosis on ureterointestinal stricture rate after radical cystectomy. J Urol (2013) 1.56
Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res (2008) 1.54
Iron chelators inhibit VCAM-1 expression in human dermal microvascular endothelial cells. J Invest Dermatol (2003) 1.53
Ureteric bud outgrowth in response to RET activation is mediated by phosphatidylinositol 3-kinase. Dev Biol (2002) 1.45
KLF5 promotes cell proliferation and tumorigenesis through gene regulation and the TSU-Pr1 human bladder cancer cell line. Int J Cancer (2006) 1.44
The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res (2006) 1.43
Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change. Am J Surg Pathol (2009) 1.43
Primary vascular tumors and tumor-like lesions of the kidney: a clinicopathologic analysis of 25 cases. Am J Surg Pathol (2010) 1.41
The impact of mechanical bowel preparation on postoperative complications for patients undergoing cystectomy and urinary diversion. J Urol (2012) 1.41
Identification and characterization of mouse metastasis-suppressor KiSS1 and its G-protein-coupled receptor. Cancer Res (2002) 1.38
Wortmannin induces homotypic fusion of plant prevacuolar compartments. J Exp Bot (2009) 1.35
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res (2002) 1.33
Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res (2013) 1.31
Renal epithelial neoplasms: diagnostic applications of gene expression profiling. Adv Anat Pathol (2008) 1.30
Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res (2009) 1.28
Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. Neoplasia (2008) 1.26
c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Blood (2009) 1.23
BFA-induced compartments from the Golgi apparatus and trans-Golgi network/early endosome are distinct in plant cells. Plant J (2009) 1.22
ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology. Eur Urol (2012) 1.19
Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer Res (2010) 1.18
DNMT1 modulates gene expression without its catalytic activity partially through its interactions with histone-modifying enzymes. Nucleic Acids Res (2012) 1.17
Sunitinib--a new standard of care for metastatic renal cell carcinoma. Nat Clin Pract Oncol (2007) 1.17
Neoplasms of the upper urinary tract: a review with focus on urothelial carcinoma of the pelvicalyceal system and aspects related to its diagnosis and reporting. Adv Anat Pathol (2008) 1.15
Overlapping and segregated resting-state functional connectivity in patients with major depressive disorder with and without childhood neglect. Hum Brain Mapp (2013) 1.15
Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer (2014) 1.14
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer (2009) 1.12
Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol Ther (2005) 1.10
Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One (2010) 1.09
Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinog (2005) 1.09
Collecting duct carcinoma versus renal medullary carcinoma: an appeal for nosologic and biological clarity. Am J Surg Pathol (2014) 1.08
FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. Clin Cancer Res (2011) 1.07
Renal tubular dysgenesis, a not uncommon autosomal recessive disorder leading to oligohydramnios: Role of the Renin-Angiotensin system. J Am Soc Nephrol (2006) 1.06
Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet. Arch Biochem Biophys (2011) 1.04
Infrequent mutation of ATBF1 in human breast cancer. J Cancer Res Clin Oncol (2006) 1.03
Activation of Wnt11 by transforming growth factor-β drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells. J Biol Chem (2012) 1.02
Ubiquitination of RhoA by Smurf1 promotes neurite outgrowth. FEBS Lett (2005) 1.01
Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. Int J Cancer (2005) 1.01
GEFT, a Rho family guanine nucleotide exchange factor, regulates neurite outgrowth and dendritic spine formation. J Biol Chem (2004) 1.01
A BAR-domain protein SH3P2, which binds to phosphatidylinositol 3-phosphate and ATG8, regulates autophagosome formation in Arabidopsis. Plant Cell (2013) 1.01
The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. Prostate (2006) 1.00
National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer (2014) 1.00
SCAMPs highlight the developing cell plate during cytokinesis in tobacco BY-2 cells. Plant Physiol (2008) 1.00
Renal neoplasms in younger adults: analysis of 112 tumors from a single institution according to the new 2004 World Health Organization classification and 2002 American Joint Committee on Cancer Staging System. Arch Pathol Lab Med (2005) 0.99
Deregulation of a Hox protein regulatory network spanning prostate cancer initiation and progression. Clin Cancer Res (2012) 0.98
Oxidative stress stimulates testicular orphan receptor 4 through forkhead transcription factor forkhead box O3a. Endocrinology (2008) 0.98
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. Am J Surg Pathol (2009) 0.96
Pseudomyxoma peritonei associated with primary mucinous borderline tumor of the renal pelvicalyceal system. Arch Pathol Lab Med (2009) 0.96
Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity. Br J Pharmacol (2013) 0.96
Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol (2011) 0.95
Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. Prostate (2006) 0.94
Androgen regulates brain-derived neurotrophic factor in spinal motoneurons and their target musculature. Endocrinology (2009) 0.93
Stress-response protein RBM3 attenuates the stem-like properties of prostate cancer cells by interfering with CD44 variant splicing. Cancer Res (2013) 0.93
Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol (2009) 0.93
Expression analysis of kidney-specific cadherin in a wide spectrum of traditional and newly recognized renal epithelial neoplasms: diagnostic and histogenetic implications. Am J Surg Pathol (2007) 0.93
Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer. PLoS One (2013) 0.93
Exo70E2 is essential for exocyst subunit recruitment and EXPO formation in both plants and animals. Mol Biol Cell (2013) 0.92
Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene (2004) 0.91
New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett (2008) 0.90
Growth kinetics of CD133-positive prostate cancer cells. Prostate (2012) 0.89
Rosai-Dorfman disease (sinus histiocytosis with massive lymphadenopathy) of the pancreas: second case report. J Gastrointest Surg (2008) 0.89
Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas. Am J Surg Pathol (2013) 0.89
Therapeutic implications of GIPC1 silencing in cancer. PLoS One (2010) 0.87
MKK4 and metastasis suppression: a marriage of signal transduction and metastasis research. Clin Exp Metastasis (2003) 0.87
Clinicopathologic analysis of choriocarcinoma as a pure or predominant component of germ cell tumor of the testis. Am J Surg Pathol (2014) 0.87
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res (2011) 0.87
Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch (2007) 0.87
The Rho-family guanine nucleotide exchange factor GEFT enhances retinoic acid- and cAMP-induced neurite outgrowth. J Neurosci Res (2006) 0.87
ARA7(Q69L) expression in transgenic Arabidopsis cells induces the formation of enlarged multivesicular bodies. J Exp Bot (2013) 0.87
Retracted Cross-talk of alpha tocopherol-associated protein and JNK controls the oxidative stress-induced apoptosis in prostate cancer cells. Int J Cancer (2012) 0.86
Maternal residential atrazine exposure and risk for choanal atresia and stenosis in offspring. J Pediatr (2012) 0.86
Apical F-actin-regulated exocytic targeting of NtPPME1 is essential for construction and rigidity of the pollen tube cell wall. Plant J (2013) 0.85
Noninvasive carcinoma of the breast: angiogenesis and cell proliferation. Arch Pathol Lab Med (2004) 0.85
Morphometric signature differences in nuclei of Gleason pattern 4 areas in Gleason 7 prostate cancer with differing primary grades on needle biopsy. J Urol (2008) 0.85
Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances. Urology (2002) 0.85
Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol (2012) 0.84
Medication treatment complexity and adherence in children with CKD. Clin J Am Soc Nephrol (2013) 0.84
Limited smoothelin expression within the muscularis mucosae: validation in bladder diverticula. Hum Pathol (2011) 0.83
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate (2014) 0.83
Comparison of open and robot-assisted pelvic lymphadenectomy for prostate cancer. J Endourol (2009) 0.83
Maternal residential atrazine exposure and gastroschisis by maternal age. Matern Child Health J (2013) 0.83